Phaseline

Companies › Genprex

Genprex: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
quaratusugene ozeplasmid
TUSC2 gene therapy - interrupts cell signaling pathways, reestablishes cancer cell death p
TUSC2Phase 1Small Cell Lung Cancer Extensive Stage; Carcinoma, Non-Small Cell LungDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05703971quaratusugene ozeplasmidPhase 1Small Cell Lung Cancer Extensive StageOncologyDec 2027
NCT04486833quaratusugene ozeplasmidPhase 1Carcinoma, Non-Small Cell LungOncologyMar 2028

From the company's SEC filings

Cash of $15m on 2026-06-30; operating cash outflow about $17m a year; runway about 11 months at that burn, to May 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

TUSC2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.